4-溴苯乙基胺氢溴酸盐 | 206559-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴苯乙基胺氢溴酸盐
• 中文别名: 4-溴苯乙胺氢溴酸；4-溴苯乙基胺 氢溴酸盐
• 英文名称: 2-(4-Bromo-phenyl)ethylamine hydrobromide
• 英文别名: 4-bromophenethylamine hydrobromide；2-(4-bromophenyl)ethanamine Hydrobromide；2-(4-bromophenyl)ethanamine;hydrobromide
• CAS: 206559-45-7
• 化学式: BrH*C₈H₁₀BrN
• mdl: MFCD00060723
• 分子量: 280.99
• InChiKey: IUWPMHYAMOUYKQ-UHFFFAOYSA-N

物化性质

• 熔点：
  272 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.16
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  27.6
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT, IRRITANT-HARMFUL, CORROSIVE
• 危险品标志：
  C,Xi
• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  4-溴苯乙基胺氢溴酸盐 在 吡啶 作用下， 以 二氯甲烷 、 硫酸 、 溶剂黄146 为溶剂， 反应 66.0h， 生成 7-溴-1,2,3,4-四氢异喹啉
  参考文献：
  名称：

  [EN] HETEROCYCLIC CYCLOPENTYL TETRAHYDROISOQUINOLINE AND TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  [FR] MODULATEURS TETRAHYDROISOQUINOLINE ET TETRAHYDROPYRIDOPYRIDINE CYCLOPENTYLES HETEROCYCLIQUES DE L'ACTIVITE DES RECEPTEURS DE CHIMIOKINE

  摘要：

  公开号：

  WO2004094371A3
• 作为产物：
  描述：

  4-溴苯乙胺 在 氢溴酸 作用下， 生成 4-溴苯乙基胺氢溴酸盐
  参考文献：
  名称：

  Renewing Halogen Substitution Strategy for the Rational Design of High‐Curie Temperature Metal‐Free Molecular Antiferroelectrics

  摘要：

  摘要 无金属分子反铁电体（AFE）因其独特的物理属性而有望用于能量存储。然而，由于缺乏有关相变能垒升高的设计策略，探索高居里温度（Tc）的分子反铁电体具有挑战性。通过更新卤素取代策略，我们获得了一系列卤素取代的苯乙基溴化铵（x-PEAB，x=H/F/Cl/Br）的高 Tc 分子 AFE，类似于二元定子-转子体系。引人注目的是，PEA+ 阳离子转子的 p 位卤素取代提高了它们的相变能垒，并大大提高了 Br-PEAB 的 Tc，最高可达 ~473 K，与分子 AFE 的创纪录高 Tc 值相当。作为一个典型案例，成员 4-氟苯乙基溴化铵（F-PEAB）显示出显著的 AFE 特性，包括高 Tc（约 374 K）和大电极化（约 3.2 μC/cm2）。此外，F-PEAB 还表现出很高的储能效率（η），即使在 Tc 附近也能达到 83.6%，赶上了其他 AFE 氧化物。分子 AFE 系统中的这种更新卤素取代策略为设计用于储能设备的高锝 AFE 提供了一种有效方法。

  DOI：

  10.1002/anie.202401221

文献信息

• Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
  申请人：Butora Gabor

  公开号：US20080081803A1

  公开（公告）日：2008-04-03

  The present invention is directed to compounds of the formula I: Wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及以下式I的化合物： 其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X、n和虚线如本文所定义，这些化合物可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。
• [EN] APO B-SECRETION/MTP INHIBITORY AMIDES<br/>[FR] AMIDES INHIBANT LA SECRETION D'Apo B ET/OU LA PROTEINE MTP
  申请人：PFIZER INC.

  公开号：WO1998023593A1

  公开（公告）日：1998-06-04

  (EN) This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors, especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin. This invention is also directed to intermediates and processes useful in the preparation of compounds of formula (I).(FR) Cette invention se rapporte à des composés représentés par la formule (I) ou aux stéréo-isomères de ces composés, et aux sels et hydrates de ces composés acceptables sur le plan pharmaceutique. Ces composés sont des inhibiteurs d'Apo B et/ou de la protéine MPT et ils sont utiles pour traiter divers troubles et états, tels que l'athérosclérose, la pancréatite, l'obésité, l'hypercholestéremie, l'hypertriglycéridémie, l'hyperlipidémie, et le diabète. Ces composés sont utiles en association avec d'autres agents pharmaceutiques, tels que les inhibiteurs de la biosynthèse du cholestérol et les inhibiteurs de l'absorption du cholestérol, en particulier les inhibiteurs de HMG-CoA réductase et les inhibiteurs des HMG-CoA synthase; des inhibiteurs d'expression des gènes de HMG-CoA réductase; les inhibiteurs de CETP; les chélateurs des acides biliaires; les fibrates; les inhibiteurs de l'absorption du cholestérol; les inhibiteurs d'ACAT, les inhibiteurs de squalène synthétase, les résines d'échange ioniques, les antioxydants et la niacine. Cette invention se rapporte également à des intermédiaires et à des procédés utiles dans la préparation de composés de la formule (I).

  本发明涉及式（I）的化合物或其立体异构体，以及其药学上可接受的盐和水合物。这些化合物是Apo B/MTP抑制剂，可用于治疗各种疾病和病症，如动脉硬化、胰腺炎、肥胖症、高胆固醇血症、高甘油三酯血症、高脂血症和糖尿病等。本发明的化合物还可与其他药物制剂联合使用，包括胆固醇生物合成抑制剂和胆固醇吸收抑制剂，特别是HMG-CoA还原酶抑制剂和HMG-CoA合酶抑制剂；HMG-CoA还原酶基因表达抑制剂；CETP抑制剂；胆酸结合树脂；纤维酸；胆固醇吸收抑制剂；ACAT抑制剂、角鲨烷合成酶抑制剂、离子交换树脂、抗氧化剂和烟酸。本发明还涉及制备式（I）化合物的中间体和有用的过程。
• Apo B-secretion/MTP inhibitory amides
  申请人：Pfizer Inc

  公开号：US06121283A1

  公开（公告）日：2000-09-19

  This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors,especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin. This invention is also directed to intermediates and processes useful in the preparation of compounds of formula (I) ##STR1##

  本发明涉及式(I)化合物或其立体异构体、药学上可接受的盐和水合物。这些化合物是Apo B/MTP抑制剂，可用于治疗各种疾病和症状，如动脉粥样硬化、胰腺炎、肥胖症、高胆固醇血症、高甘油三酯血症、高脂血症和糖尿病。该发明的化合物还可与其他药物剂合用，包括胆固醇生物合成抑制剂和胆固醇吸收抑制剂，特别是HMG-CoA还原酶抑制剂和HMG-CoA合成酶抑制剂；HMG-CoA还原酶基因表达抑制剂；CETP抑制剂；胆汁酸结合树脂；纤维酸类；胆固醇吸收抑制剂；ACAT抑制剂、角鲨烷合酶抑制剂、离子交换树脂、抗氧化剂和烟酸。本发明还涉及中间体和有用于制备式(I)化合物的过程。
• Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide
  申请人：Pfizer INc.

  公开号：US05919795A1

  公开（公告）日：1999-07-06

  Compounds of formula (I), ##STR1## wherin X is CH.sub.2, CO, CS or SO.sub.2 ; Y is selected from: a direct link, aliphatic hydrocarbylene radicals having up to 20 carbon atoms, which radical may be mono-substituted by hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, or (C.sub.6 -C.sub.10)aryl, NH, and O, provided that if X is CH.sub.2,Y is a direct link; Z is selected from the following groups: (1) H, halo, cyano, (2) hydroxy, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)a1kylthio, (C.sub.1 -C.sub.10)acyl, thiophenylcaronyl (C.sub.1 -C.sub.10)alkoxycarbonyl, (3) (C.sub.1 -C.sub.10)aklkyammo, di(C.sub.1 -C.sub.10)alylamino, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylamino, provided that Y is not O or NH, (4) unsubstituted vinyl, (C.sub.6 -C.sub.10)aryl, (C.sub.3 -C.sub.8)cycloalkyl and fused benz derivatives thereof, (C.sub.7 -C.sub.10)polycycloalkyl, (C.sub.4 -C.sub.8)cycloalkenyl, (C.sub.7 -C.sub.10)polycycloalkenyl, (5) (C.sub.6 -C.sub.10)aryloxy, (C.sub.6 -C.sub.10)aryltio, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkoxy, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.10)alkylthio, (C.sub.3 -C.sub.8)cycloalkyloxy, (C.sub.4 -C.sub.8)cycloalkenyloxy, (6) heterocyclyl sclected from the group consisting of monocyclic radicals and fused polycycuic radicals, wherein said radicals contain a total of from 5 to 14 ring atoms, wherein said radicals contain a total of from 1 to 4 ring heteroatoms independently selocted from oxygen, nitrogen, and sulfur, and wherein the individual rings of said radicals may be independendy satated, partally unsaturated, or aromatic, provided that if X is CH.sub.2, Z is H or is selected from groups (4) and (6), wherein, when Z contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from halo, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy, (C.sub.1 -C.sub.10)alkyl, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)alkoxycarbonyl, (C.sub.1 -C.sub.10)althyltio, (C.sub.1 -C.sub.10)altylamino, (C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkylamino, di(C.sub.1 -C.sub.10)alkylaminocarbonyl, di(C.sub.1 -C.sub.10)alkyo(C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.3)perfluoroalkyl, (C.sub.1 -C.sub.3)perfluoroalkoxy, (C.sub.1 -C.sub.10)acyl, (C.sub.1 -C.sub.10)acyloxy, (C.sub.1 -C.sub.10)acyloxy(C.sub.1 -C.sub.10)alkyl, and pyrrolidinyl; and pharmaceutically acceptable salts thereof.

  化合物的公式(I)，其中X为CH.sub.2，CO，CS或SO.sub.2; Y从以下选取：直接连接，具有最多20个碳原子的脂肪烃基，该基可能被羟基，(C.sub.1-C.sub.10)烷氧基，(C.sub.1-C.sub.10)酰基，(C.sub.1-C.sub.10)酰氧基或(C.sub.6-C.sub.10)芳基单取代，NH和O，前提是如果X为CH.sub.2，则Y为直接连接；Z从以下组中选取：(1) H，卤素，氰基，(2) 羟基，(C.sub.1-C.sub.10)烷氧基，(C.sub.1-C.sub.10)烷基硫基，(C.sub.1-C.sub.10)酰基，硫代苯甲酰基，(C.sub.1-C.sub.10)烷氧羰基，(3) (C.sub.1-C.sub.10)烷氨基，二(C.sub.1-C.sub.10)烷基氨基，(C.sub.6-C.sub.10)芳基(C.sub.1-C.sub.10)烷基氨基，前提是Y不是O或NH，(4) 未取代的乙烯基，(C.sub.6-C.sub.10)芳基，(C.sub.3-C.sub.8)环烷基及其融合苯衍生物，(C.sub.7-C.sub.10)多环环烷基，(C.sub.4-C.sub.8)环烯基，(C.sub.7-C.sub.10)多环环烯基，(5) (C.sub.6-C.sub.10)芳氧基，(C.sub.6-C.sub.10)芳硫基，(C.sub.6-C.sub.10)芳基(C.sub.1-C.sub.10)烷氧基，(C.sub.6-C.sub.10)芳基(C.sub.1-C.sub.10)烷基硫基，(C.sub.3-C.sub.8)环烷氧基，(C.sub.4-C.sub.8)环烯氧基，(6) 来自单环基和融合多环基的杂环基，其中所述基团包含从5到14个环原子的总数，其中所述基团包含从氧，氮和硫中独立选择的1到4个环杂原子，其中所述基团的各个环可以独立饱和，部分不饱和或芳香性，前提是如果X为CH.sub.2，则Z为H或从组(4)和(6)中选择的基团，其中，当Z含有一个或多个环时，所述环可以各自独立地承载0到4个取代基，所述取代基独立选择自卤素，羟基，氰基，硝基，氧化物，硫代氧化物，氨基磺酰基，苯基氧基，苯基硫基，卤苯基硫基，苄基，苄氧基，(C.sub.1-C.sub.10)烷基，(C.sub.1-C.sub.10)烷氧基羰基，(C.sub.1-C.sub.10)烷硫基，(C.sub.1-C.sub.10)烷基氨基，(C.sub.1-C.sub.10)烷基氨基羰基，二(C.sub.1-C.sub.10)烷基氨基，二(C.sub.1-C.sub.10)烷基氨基羰基，二(C.sub.1-C.sub.10)烷氧基(C.sub.1-C.sub.10)烷氧基，(C.sub.1-C.sub.3)全氟烷基，(C.sub.1-C.sub.3)全氟烷氧基，(C.sub.1-C.sub.10)酰基，(C.sub.1-C.sub.10)酰氧基，(C.sub.1-C.sub.10)酰氧(C.sub.1-C.sub.10)烷基和吡咯烷基；以及其药学上可接受的盐。
• Optimizing Broadband Emission in 2D Halide Perovskites
  作者：Carina Pareja-Rivera、Julio A. Morán-Muñoz、A. Paulina Gómora-Figueroa、Vojtech Jancik、Brenda Vargas、Joelis Rodríguez-Hernández、Diego Solis-Ibarra

  DOI：10.1021/acs.chemmater.2c00937

  日期：2022.11.8

  phosphors and LEDs. Some two-dimensional (2D) halide perovskites are promising candidates in this realm. Nevertheless, optimizing their photoluminescence quantum efficiency (PLQY) is highly challenging. Herein, we show a new strategy for optimizing the efficiency of the broadband emission of 2D halide perovskites. Specifically, we show that by a combination of halide bonds and halide mixing, the PLQYs

  宽带和白光发射材料在荧光粉和 LED 等应用中受到追捧。一些二维（2D）卤化物钙钛矿是该领域有前途的候选者。然而，优化它们的光致发光量子效率（PLQY）是极具挑战性的。在此，我们展示了一种优化二维卤化物钙钛矿宽带发射效率的新策略。具体来说，我们表明，通过结合卤化物键和卤化物混合，具有分子式 (Br-PEA) 2 PbBr x Cl 4– x (Br-PEA = 4-bromo phenethylammonium) 的新型材料家族的 PLQY 可以提高了一个数量级，从 3% 提高到 25%；这种方法可能对许多其他二维钙钛矿有用。